QbD:Regulatory and Scientific Possibilities and Challenges
Gert Ragnarsson, Director of the Swedish Medical Projects Agency, discusses the biggest milestones in QbD over the last decade, including:
The establishment of harmonised guidelines
The Formation of the EMA
The recent document published by the FDA, which is a significant step in dealing with advanced formulations
He also looks to the future growth of generics and the effects QbD and PAT will have on that market.
TO READ THE FULL STORY
Please note: That all fields marked with an asterisk (*) are required.